First Noema clinical trial, with asset in-licensed from Roche with strong clinical safety package Noema advancing potentially life-changing therapeutics for patients without satisfactory treatments Basel, August 5, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the initiation of its first clinical trial, a Phase 2a […]
BASEL, Switzerland, July 7, 2021, Basel, Switzerland – Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, will host a key opinion leader (KOL) webinar on seizures in tuberous sclerosis complex (TSC) on Tuesday, July 20, 2021 at 4pm CET / 10am Eastern Time. The webinar will feature a presentation by Dr
BASEL, Switzerland, May 31, 2021, Basel, Switzerland – Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, today announces it will attend several investor conferences during June and July. Luigi Costa, Chief Executive Officer, and George Garibaldi, Chief Medical Officer, will present the latest developments at Noema Pharma following the oversubscribed Series
Noema Pharma to Attend Investor Conferences in June and July 2021 Read More »
